Open Access

Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study

  • Martin Heier1, 2, 3Email authorView ORCID ID profile,
  • Hanna Dis Margeirsdottir2, 3, 4,
  • Mario Gaarder5,
  • Knut Haakon Stensæth2, 5,
  • Cathrine Brunborg6,
  • Peter Abusdal Torjesen2, 7,
  • Ingebjørg Seljeflot2, 8,
  • Kristian Folkvord Hanssen2, 3, 9 and
  • Knut Dahl-Jørgensen1, 2, 3
Cardiovascular Diabetology201514:126

https://doi.org/10.1186/s12933-015-0292-2

Received: 25 June 2015

Accepted: 17 September 2015

Published: 25 September 2015

Abstract

Background

Advanced glycation end products (AGEs) play a role in the development of late complications and atherosclerosis in diabetes by engaging the receptor for advanced glycation end products, RAGE. Receptor binding leads to activation of the vascular endothelium and increased inflammation in the vessel wall. The soluble variants of the receptor, endogenous secretory RAGE (esRAGE) and the cleaved cell-surface part of RAGE, which together comprise soluble RAGE (sRAGE), are suggested to have a protective effect acting as decoys for RAGE. We aimed to test whether high levels of soluble variants of RAGE could be protective against atherosclerosis development.

Methods

Participants in the prospective atherosclerosis and childhood diabetes study were examined at baseline (aged 8–18) and at follow-up after 5 years. Both sRAGE and esRAGE were measured by immunoassay in 299 patients with type 1 diabetes and 112 healthy controls at baseline and 241 patients and 128 controls at follow-up. The AGEs methylglyoxal-derived hydroimidazolone-1 (MG-H1) and carboxymethyllysine (CML) were measured by immunoassay. The surrogate markers of atherosclerosis assessed were carotid intima-media thickness (cIMT), C-reactive protein (CRP) and Young’s modulus, measures of arterial wall thickness, inflammation and arterial stiffness, respectively.

Results

Levels of sRAGE and esRAGE correlated strongly both at baseline and at follow-up in both diabetes patients and controls. With increasing age, mean values of both variants declined, independent of gender, diabetes or pubertal stage. In the diabetes group, multiple regression analysis showed a positive association between both variants of soluble RAGE and cIMT. There was no significant relationship with Young’s modulus, but a negative association between sRAGE at baseline and CRP at follow-up. The ratios between the AGEs and the variants of soluble RAGE were increased in diabetes patients compared to controls.

Conclusions

The results show a possible protective effect of high levels of sRAGE at baseline against inflammation 5 years later, but not on arterial stiffness or wall thickness, in this cohort of adolescents and young adults with T1D.

Keywords

Advanced glycation end products Receptor for advanced glycation end products sRAGE esRAGE Atherosclerosis Type 1 diabetes CRP

Background

Advanced glycation end products (AGEs) have been implicated in the pathogenesis of both microvascular complications and accelerated atherosclerosis in type 1 diabetes (T1D) [1, 2]. A proposed mechanism for the deleterious effect of AGEs is engagement of the receptor for AGEs, RAGE, which is a multiligand transmembrane receptor in the immunoglobulin superfamily present on the surface of various cell types in atherosclerotic lesions [35]. Two of the AGEs that potentially bind to RAGE are carboxymethyllysine (CML) and methylglyoxal-derived hydroimidazolone-1 (MG-H1) [6, 7]. Receptor binding leads to activation of monocytes and the vascular endothelium and increases inflammation in the vessel wall [8, 9]. A mouse cell model indicates that RAGE also mediates AGE-induced macrophage migration [10].

RAGE has two soluble forms prevalent in human plasma. One created as the membrane bound receptor is cleaved by metalloproteinases [11], and the other produced by alternative splicing of the RAGE gene [12]. The latter is known as endogenous secretory RAGE (esRAGE) [13], and together they constitute plasma soluble RAGE (sRAGE). Estimates indicate that esRAGE accounts for 20–50 % of sRAGE [14, 15].

It has been postulated that both soluble variants of RAGE work as decoys for AGEs, reducing RAGE signaling and inflammation [16]. In a mouse model, treatment with intraperitoneal sRAGE suppressed the accelerated atherosclerosis of diabetes [17]. This suggests that high levels of sRAGE protect against the atherogenic effect of AGEs. Studies in T1D have, however, shown conflicting results. Levels of soluble variants of RAGE both lower [1820] and higher [2123] than controls have been demonstrated. Previously, Katakami et al. have found an inverse association between levels of esRAGE and carotid intima media thickness (cIMT) both cross-sectionally [18] and longitudinally in young adults [24]. Nin et al., however, showed a positive association between sRAGE and cardiovascular events and all-cause mortality [22, 25]. The seemingly contradictory results might be due to the different ethnic origin of the study populations [26], but more likely reflect the complexity of the regulation of the AGE-RAGE-sRAGE and AGE-RAGE-esRAGE axes. This implies that AGEs or sRAGE alone may not be particularly informative as biomarkers, and an AGE/sRAGE ratio has been proposed as an improvement [27].

In this study, we aimed to investigate longitudinally whether higher levels of soluble variants of RAGE protect against atherosclerosis development in young patients with T1D compared to healthy controls.

Methods

Study population

The atherosclerosis and childhood diabetes (ACD) prospective study was initiated in 2006, comprising 314 diabetes patients and 120 controls, all between 8 and 18 years old, from the South East health region of Norway. The non-diabetic controls were mainly classmates of the diabetes patients. The details of the cohort and inclusion process have previously been described [28]. From 2011 to 2013, the participants were encouraged to attend a 5-year follow-up, and 80 % agreed. An additional 38 control subjects were also enrolled at this time.

Both at baseline and at follow-up, blood samples were taken in the morning between 0800 and 1000 a.m. after an overnight fast. This was followed by carotid ultrasound and a clinical examination.

All parents and participants over 18 years old have given their written informed consent. The protocol, both at baseline and follow-up has been approved by the Norwegian Regional Committee for Research Ethics, and the study has been conducted according to the Declaration of Helsinki.

Laboratory methods

All blood samples were centrifuged at 2500×g for 10 min immediately after venipuncture and stored at −80 °C until analysis. Serum sRAGE and esRAGE were measured using enzyme-linked immunosorbent assay (ELISA) kits (Quantikine, R&D Systems, Minneapolis, MN, USA and B-Bridge International Inc., Cupertino, CA, USA respectively) according to the manufacturer’s instructions. The inter-assay coefficients of variation (CV) in our laboratory were 5.8 % for sRAGE and 5.7 % for esRAGE. At baseline 411 participants (299 diabetes patients, 112 controls) had valid measurements. At follow-up 369 (241 diabetes patients and 128 controls) were tested. 318 participants (231 diabetes patients and 87 controls) had measurements at both baseline and follow-up. All samples from both timepoints were measured in the same run to avoid bias due to assay variability.

MG-H1 and CML were measured by dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA) as previously described in detail [2931].

Images of the common carotid arteries (CCAs) at baseline were obtained using a Siemens Acuson Sequoia 512 (Siemens Acuson; Mountain View, CA, USA) ultrasound scanner equipped with a linear array 14 MHz transducer. Further details have been described previously [28]. At follow-up, the images of the CCAs were obtained using a Zonare Z-one ULTRA (Zonare Medical Systems; Mountain View, CA, USA) ultrasound scanner equipped with a linear array 8 MHz transducer. The cIMT measurements were performed using M’Ath 3.2.0 (Intelligence in Medical Imaging; Paris, France). All cIMT measurements were from the far wall in end-diastole. Blood pressure for calculating Young’s modulus was assessed using a standard oscillometric device over the brachial artery.

CRP was determined by high sensitivity ELISA (DRG Instruments GmbH, Germany) with a detection limit of 0.1 mg/L. The inter-assay CV was <5 %.

HbA1c was measured at a DCCT-standardized laboratory using high performance liquid chromatography (Variant; Bio-Rad, Richmond, CA, USA), CV <3 %. Other routine laboratory analyses were performed by conventional methods.

Statistical analysis

Demographic and clinical data are presented as either proportions, means with their standard deviations (SD) or medians with the 25th and 75th percentile. Differences in continuous variables between groups were tested with the Student t test, alternatively the Mann–Whitney U-test for non-normally distributed data. Correlation analyses between continous variables were performed using Pearson’s correlation coefficient (r) for normally distributed data, or otherwise Spearman’s rho (ρ). Univariate linear regression analysis was performed to identify associations between sRAGE and esRAGE as exposure variables and surrogate markers of atherosclerosis as outcome variables. Only variables with significant relationships with both the exposure and the outcome variables were considered as possible confounders and included in a multivariate analysis. Adjustment for multiple confounding factors was performed using multivariate linear regression analysis with a manual backward elimination procedure. CRP was loge-transformed to achieve normally distributed residuals. A significance level of 5 % was used.

In addition, multivariate linear regression analysis with a manual backward elimination procedure was performed to identify predictors for soluble variants of RAGE at follow-up. Any variable with a p value <0.20 from the univariate analysis was considered a candidate for the multivariate model. All statistical analyses were performed using the SPSS software package for Mac, version 19.0 (SPSS, Chicago, IL, USA).

Results

Most of the diabetes patients (97 %) were on intensive insulin treatment using insulin pumps or >4 insulin injections a day. At baseline, comparison with the Norwegian Childhood Diabetes Registry showed that our cohort was a representative sample of the young T1D population in Norway regarding gender, stage of puberty, HbA1c, blood pressure and lipid status [28]. Due to exclusion of participants under 8 years of age, the patients in our cohort were slightly older, had longer diabetes duration, higher body mass index (BMI) and were more frequently pump users than the rest of the Norwegian children and adolescents with diabetes. The clinical and metabolic characteristics of the patients at baseline and follow-up are shown in Table 1. The diabetic patients had higher body weight, blood pressure and increased serum lipid levels compared to the control subjects both at baseline and at follow-up.
Table 1

Clinical and metabolic characteristics

 

Baseline

5 year follow-up

Diabetes (n = 299)

Controls (n = 112)

p value

Diabetes (n = 241)

Controls (n = 128)

p value

Diabetes duration (years)a

5.1 (2.9, 7.7)

  

9.6 (7.5, 12.6)

  

Insulin pump users (%)

53.3

  

61.3

  

Age (years)

13.7 (2.8)

13.4 (2.5)

0.207

18.7 (2.8)

18.7 (2.9)

0.895

Girls, n (%)

150 (50.2)

64 (57.1)

0.224

129 (53.5)

72 (56.3)

0.661

Height (cm)

160.5 (14.4)

157.6 (13.3)

0.060

171.2 (9.1)

172.1 (9.2)

0.383

Weight (kg)

54.8 (16.7)

48.5 (13.2)

<0.001

71.0 (14.6)

66.9 (12.5)

0.006

BMI (kg/m2)

20.8 (3.9)

19.2 (3.1)

<0.001

24.1 (4.3)

22.5 (3.4)

<0.001

Waist circumference (cm)

71.1 (10.0)

66.8 (6.6)

<0.001

79.0 (9.6)

75.5 (8.2)

<0.001

Systolic blood pressure (mmHg)

101 (10.1)

98 (10)

0.025

112 (11)

111 (10)

0.656

Diastolic blood pressure (mmHg)

60 (8)

58 (7)

0.017

70 (8)

68 (8)

0.024

HbA1c (%) [mmol/mol, SD]

8.4 (1.2) [68, 13.1]

5.3 (0.3) [34, 3.3]

<0.001

9.0 (1.4) [75, 15.3]

5.2 (0.3) [33, 3.3]

<0.001

Total cholesterol (mmol/L)

4.6 (0.8)

4.3 (0.7)

0.001

4.8 (1.0)

4.4 (1.0)

0.001

HDL (mmol/L)

1.8 (0.4)

1.7 (0.4)

0.048

1.6 (0.5)

1.6 (0.4)

0.161

LDL (mmol/L)

2.5 (0.7)

2.3 (0.7)

0.016

2.7 (0.8)

2.5 (0.8)

0.014

Triglycerides (mmol/L)a

0.7 (0.5, 0.9)

0.7 (0.5, 0.9)

0.367

0.9 (0.6, 1.3)

0.8 (0.6, 1.0)

0.024

Apolipoprotein B (g/L)

0.74 (0.19)

0.66 (0.17)

<0.001

0.90 (0.26)

0.79 (0.23)

<0.001

Apolipoprotein A1 (g/L)

1.55 (0.28)

1.44 (0.33)

0.001

1.56 (0.31)

1.48 (0.27)

0.006

ApoB/ApoA1

0.5 (0.2)

0.5 (0.3)

0.698

0.6 (0.2)

0.5 (0.2)

0.025

Urine albumin/creatinine (mg/mmol)a

0.70 (0.40, 1.30)

0.63 (0.36, 1.33)

0.688

0.65 (0.30, 1.55)

0.34 (0.19, 0.90)

0.001

Mean values (SD)

aMedian (25th and 75th percentile)

The results from the sRAGE and esRAGE assays and the measurements of surrogate markers of atherosclerosis are presented in Table 2. We found no difference in soluble variants of RAGE between the groups, except for lower levels of esRAGE in the diabetes group at baseline. As for cIMT and Young’s modulus, we found no significant differences between the groups. CRP was significantly elevated in the diabetes group both at baseline [32] and at follow-up.
Table 2

Soluble RAGE and surrogate markers of atherosclerosis

 

Baseline

5 year follow-up

Diabetes

Controls

p value

Diabetes

Controls

p value

sRAGE (pg/ml)

1664 (602)

1773 (574)

0.100

1578 (589)

1585 (561)

0.909

esRAGE (ng/ml)

0.36 (0.16)

0.42 (0.16)

<0.001

0.33 (0.21)

0.33 (0.13)

0.810

cIMT (mm)

0.45 (0.05)

0.44 (0.04)

0.067

0.51 (0.05)

0.51 (0.06)

0.324

Young’s modulus (kPa)

13.7 (2.8)

13.4 (2.5)

0.207

18.7 (2.8)

18.7 (2.9)

0.895

CRP (mg/l)a

0.50 (0.27, 1.84)

0.31 (0.19, 0.67)

<0.001

1.16 (0.43, 3.64)

0.69 (0.28, 2.00)

0.002

Mean values (SD)

aMedian (25th and 75th percentile)

The levels of sRAGE and esRAGE correlated strongly, both in the diabetes and the control group (Table 3). In the diabetes group, the boys had significantly higher sRAGE both at baseline [1752 (SD = 609) vs. 1576 (SD = 584) pg/ml, p = 0.011] and at follow-up [1682 (SD = 609) vs. 1487 (SD = 557) pg/ml, p = 0.010] as well as higher esRAGE at baseline [0.39 (SD = 0.17) vs. 0.34 (SD = 0.15) ng/ml, p = 0.005] than the girls. These differences disappeared when excluding the girls using oral contraceptives from the analysis.
Table 3

Coefficients of correlation (Pearson), all with p < 0.001

 

Diabetes group

Control group

esRAGE baseline

esRAGE follow-up

sRAGE baseline

esRAGE baseline

esRAGE follow-up

sRAGE baseline

esRAGE follow-up

0.396

1

 

0.636

1

 

sRAGE baseline

0.800

0.295

1

0.775

0.597

1

sRAGE follow-up

0.593

0.510

0.638

0.458

0.828

0.620

At baseline, there was a weak negative correlation between HbA1c and sRAGE (r = −0.148, p = 0.011) and esRAGE (r = −0.137, p = 0.018). There were no significant correlations with HbA1c at follow-up or in the control group at any time point.

Natural progression of sRAGE and esRAGE

There was a decline in sRAGE and esRAGE levels with increasing age. Figure 1 shows levels of sRAGE in diabetes patients and controls. For illustrative purposes, values from each patient at both baseline and follow-up are included. The graphs for esRAGE as well as for both soluble variants of RAGE when separated by gender showed similar patterns. There was no decline in the levels of either soluble variant of RAGE across the five Tanner stages of puberty.
Fig. 1

Mean sRAGE and age. Values in diabetes patients (grey line) and controls (dotted line). The figure includes two values from each participant, one at baseline and one at follow-up

To determine whether this relationship with age was confounded by other factors, we performed regression analyses. At baseline, the association between age and esRAGE remained significant after controlling for the confounding effect of CRP in the diabetes group (B = −0.009, R2 = 0.082 and p = 0.009) and in girls with diabetes (B = −0.012, R2 = 0.123 and p = 0.008). Also, sRAGE was significantly associated with age in the control group (B = −47.1, R2 = 0.081 and p = 0.033, controlling for MG-H1), in girls with diabetes (B = −61.6, R2 = 0.154 and p = 0.001, controlling for CRP) and in control girls (B = −99.1, R2 = 0.154 and p = 0.001, no confounding variables). At follow-up, esRAGE was not associated with age in any group. There was, however, significant associations between sRAGE and age in the diabetes group (B = −51.5, R2 = 0.131 and p < 0.001, controlling for CRP), in boys with diabetes (B = −57.8, R2 = 0.071 and p = 0.004, no confounding variables) and in girls with diabetes (B = −45.5, R2 = 0.152 and p = 0.016, controlling for CRP). When identifying predictors of esRAGE or sRAGE in the different groups, age was only significant for sRAGE at follow-up in the diabetes group.

Soluble variants of RAGE and atherosclerosis

In multiple regression analyses we found significant associations between soluble variants of RAGE and the surrogate markers of atherosclerosis cIMT and CRP in the diabetes group. These are presented in Table 4. There were no significant associations in the control group, and there were no significant associations involving Young’s modulus in either group.
Table 4

Significant associations in the diabetes group

Independent variable

Dependent variable

Beta value

SE

p value

R2

Confounding variables

Baseline esRAGE

Follow-up cIMT

0.074

0.023

0.001

0.141

Gender, waist circumference, BMI

Baseline sRAGE

Follow-up cIMT

1.4 × 10−5

6.2 × 10−6

0.027

0.116

Gender, waist circumference, ApoB

Baseline sRAGE

Follow-up CRP

−3.3 × 10−4

1.4 × 10−4

0.017

0.269

Height, medication, BMI

We also analyzed delta values (follow-up minus baseline). We found no significant associations between baseline variants of soluble RAGE and delta CRP in either patient group. Due to different measurement techniques applied at each time point, we were unable to evaluate delta values for cIMT and Young’s modulus. Delta sRAGE and delta esRAGE were not correlated with either delta HbA1c, delta LDL or delta BMI.

AGE/soluble variants of RAGE ratios

At baseline, levels of MG-H1 were significantly increased in the diabetes group compared to controls, 154.4 (SD = 40.8) vs. 142.8 (SD = 35.5) U/ml, p = 0.008. There was no significant difference in CML, 18.0 (SD = 4.4) vs. 17.3 (SD = 5.7) U/ml, p = 0.152. All possible AGE/soluble variants of RAGE ratios at baseline were significantly increased in the diabetes patients compared to controls (Table 5). In multivariate analyses, there were no significant associations between AGE/soluble variants of RAGE ratios at baseline and surrogate markers of atherosclerosis 5 years later.
Table 5

AGE/soluble RAGE ratios

Ratio

Diabetes patients

Controls

p value

MG-H1/sRAGE

0.099 (0.071, 0.124)

0.083 (0.058, 0.117)

0.006

MG-H1/esRAGE

461 (335,624)

332 (248,480)

<0.001

CML/sRAGE

0.012 (0.008, 0.015)

0.010 (0.007, 0.013)

0.005

CML/esRAGE

53.4 (39.8, 72.4)

38.1 (28.6, 58.6)

<0.001

Median (25th, 75th percentile)

Discussion

The main findings in this study are the relationships between the soluble variants of RAGE and surrogate markers of atherosclerosis. Our analyses do not indicate a protective effect of high levels of sRAGE or esRAGE against atherosclerosis development measured by cIMT. In fact, in the diabetes group we found the opposite, that high levels of both sRAGE and esRAGE at baseline are significantly associated with higher cIMT 5 years later. This is in line with the studies by Nin et al. [22, 25]. On the other hand, baseline sRAGE was significantly negatively associated with CRP, indicating a protective effect against inflammation. We found no significant associations between soluble variants of RAGE and any measure of atherosclerosis in the control group.

We have demonstrated a reduction in values of both sRAGE and esRAGE in the teens and early twenties, regardless of diabetes, gender, or pubertal stage. The association with age remained significant in several groups when controlling for confounding factors, particularly in girls. A similar reduction with increasing age has been shown in women below the age of 35 compared to older subjects [33]. Komosinska-Vassev et al. have also shown decreasing esRAGE values with increasing age in subjects without significant disease, particularly in women [34]. The participants in our study were young and healthy, apart from T1D. The fact that we did not find an association between T1D and the reduction in sRAGE or esRAGE values suggests that this is a normal physiologic development. Most studies, however, show a significant relationship between soluble variants of RAGE and disease states [35]. High levels of sRAGE are associated with healthy aging [36], but whether sRAGE is protective against disease, reduced in disease, or both, is unknown.

The strong correlation between baseline and follow-up values of both sRAGE and esRAGE indicate that changes in levels of soluble variants of RAGE over time in each patient are generally small. We also found strong correlations between sRAGE and esRAGE both at baseline and follow-up. This suggests that esRAGE constitutes a large proportion of the measured sRAGE and consequently that the cleaved form of RAGE is less prevalent. This is in contrast to most other studies, where esRAGE is estimated to constitute only 20 % of sRAGE [11, 14, 37, 38]. A possible explanation is that our subjects are younger and healthier than in the previous studies. This is supported by the only study that has assessed the levels of sRAGE and esRAGE using comparable immunoassays [15]. Higher levels of esRAGE compared to sRAGE in youth is reasonable since RAGE amplifies inflammation [9]. Older patients with more pronounced atherosclerosis or other inflammatory diseases would express more RAGE on the cell surface and subsequently release more cleaved RAGE into the circulation [39].

The regulation of the AGE-RAGE-sRAGE and AGE-RAGE-esRAGE axes is only partly understood. RAGE is subject to regulated intramembrane proteolysis by ADAM10 (a disintegrin and metalloproteinase 10), shedding the cleaved variant of sRAGE in a process dependent on intracellular calcium levels [40]. Shedding can also be induced by activation of G protein-coupled receptors [41]. As for esRAGE, engagement of RAGE by methylglyoxal-modified human serum albumin stimulated production of RAGE and esRAGE to a similar extent in human umbilical vein endothelial cells. Interestingly, engagement of RAGE by carboxymethyllysine-modified human serum albumin more selectively stimulated production of RAGE [42]. Ohe et al. have shown that elements in exon 9B of the RAGE gene can modulate the ratio of RAGE/esRAGE production [43]. Levels of sRAGE are associated with albuminuria, indicating that kidney function is important for esRAGE excretion [38]. Still, much is yet left to discover about the production and excretion of the soluble variants of RAGE. Even though sRAGE in our study was negatively associated with CRP 5 years later, this does not necessarily imply a causal relationship. The finding indicates a protective effect, but as inflammation most likely alters the AGE-RAGE-sRAGE and AGE-RAGE-esRAGE axes in a still unpredictable fashion, sound conclusions are difficult to reach.

The AGE/sRAGE ratio has been proposed as an improved biomarker for the AGE-RAGE-sRAGE axis [27]. A higher ratio is associated with pre-eclampsia in women with T1D [44], and we also found higher ratios in diabetes patients compared to controls in this study. However, we found no significant associations with surrogate markers of atherosclerosis, rendering the ratios less useful than sRAGE alone. Furthermore, the ratios are hardly easier to interpret than the separate factors, as the influence of other AGEs, membrane bound RAGE, production and excretion of sRAGE and esRAGE are still unknown.

Strengths and limitations

The strengths of this study include the prospective design, relatively large cohort of diabetes patients and controls and different surrogate markers of atherosclerosis. There are of course also limitations. Non-invasive measurement of atherosclerosis in children and young adults have several inherent shortcomings. Only cIMT and CRP are accepted surrogate markers of atherosclerosis, and best documented in adults [45]. Young’s modulus is not the gold standard for measuring arterial stiffness, which introduces some uncertainty. It is debatable whether AGE’s in the concentration found in vivo actually are important ligands for RAGE, and there are several other classes of ligands for RAGE not considered in this study, including the proteins S100/calgranulin and high mobility group box 1 (HMGB1) and others [46, 47]. As long as the AGE-RAGE-sRAGE and AGE-RAGE-esRAGE axes are insufficiently understood, the data must be interpreted with caution.

Conclusions

In this study, we have shown a possible protective effect of high levels of sRAGE on inflammation, but not on arterial stiffness or wall thickness, in this cohort of adolescents and young adults with T1D. We have also shown an age-associated decline in values of both sRAGE and esRAGE in the teens and early twenties of both T1D patients and healthy control subjects.

Abbreviations

AGE: 

advanced glycation end product

RAGE: 

receptor for AGEs

esRAGE: 

endogenous secretory RAGE

sRAGE: 

soluble RAGE

MG-H1: 

methylglyoxal-derived hydroimidazolone-1

CML: 

carboxymethyllysine

cIMT: 

carotid intima-media thickness

CRP: 

C-reactive protein

T1D: 

type 1 diabetes

ACD: 

atherosclerosis and childhood diabetes

ELISA: 

enzyme-linked immunosorbent assay

CV: 

coefficient of variation

DELFIA: 

dissociation-enhanced lanthanide fluorescent immunoassay

CCA: 

common carotid artery

SD: 

standard deviation

ADAM10: 

a disintegrin and metalloproteinase 10

HMGB1: 

high mobility group box 1

Declarations

Authors’ contributions

MH collected data, performed statistical analysis and drafted the manuscript. HDM participated in the design of the study and collected data. MG performed the ultrasound and elasticity assessments. KHS participated in the design of the study and performed cIMT measurements. CB performed statistical analysis. PAT carried out immunoassays. IS carried out blood sample analysis. KFH participated in the design and coordination of the study. KDJ conceived of the study and participated in the design and coordination. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to thank ExtraStiftelsen Helse og Rehabilitering for providing funds essential to the establishment of this study.

We would also like to thank René og Bredo Grimsgaard’s Stiftelse for their generous donation, making the sRAGE and esRAGE analyses possible.

We are very grateful to Eva Bressendorf Lindseth for her contribution in collecting and handling the data.

Compliance with ethical guidelines

Competing interests The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Pediatric Department, Oslo University Hospital
(2)
Faculty of Medicine, University of Oslo
(3)
Oslo Diabetes Research Centre
(4)
Akershus University Hospital
(5)
Department of Radiology and Nuclear Medicine, Oslo University Hospital
(6)
Department of Biostatistics and Epidemiology, Oslo University Hospital
(7)
Hormone Laboratory, Oslo University Hospital
(8)
Department of Cardiology, Center for Clinical Heart Research, Oslo University Hospital
(9)
Department of Endocrinology, Oslo University Hospital

References

  1. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615–25.View ArticlePubMedGoogle Scholar
  2. Jandeleit-Dahm K, Cooper ME. The role of AGEs in cardiovascular disease. Curr Pharm Des. 2008;14:979–86.View ArticlePubMedGoogle Scholar
  3. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267:14998–5004.PubMedGoogle Scholar
  4. Ritthaler U, Deng Y, Zhang Y, Greten J, Abel M, Sido B, et al. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol. 1995;146:688–94.PubMed CentralPubMedGoogle Scholar
  5. Soulis T, Thallas V, Youssef S, Gilbert RE, McWilliam BG, Murray-McIntosh RP, et al. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia. 1997;40:619–28.View ArticlePubMedGoogle Scholar
  6. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem. 1999;274:31740–9.View ArticlePubMedGoogle Scholar
  7. Xue J, Ray R, Singer D, Bohme D, Burz DS, Rai V, et al. The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs. Biochemistry. 2014;53:3327–35.PubMed CentralView ArticlePubMedGoogle Scholar
  8. Figarola JL, Shanmugam N, Natarajan R, Rahbar S. Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes. 2007;56:647–55.View ArticlePubMedGoogle Scholar
  9. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation. 2002;105:816–22.View ArticlePubMedGoogle Scholar
  10. Qin Q, Niu J, Wang Z, Xu W, Qiao Z, Gu Y. Heparanase induced by advanced glycation end products (AGEs) promotes macrophage migration involving RAGE and PI3 K/AKT pathway. Cardiovasc Diabetol. 2013;12:37.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008;22:3716–27.View ArticlePubMedGoogle Scholar
  12. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J. 2008;22:1572–80.View ArticlePubMedGoogle Scholar
  13. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2003;370:1097–109.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:2587–93.View ArticlePubMedGoogle Scholar
  15. Yamamoto Y, Miura J, Sakurai S, Watanabe T, Yonekura H, Tamei H, et al. Assaying soluble forms of receptor for advanced glycation end products. Arterioscler Thromb Vasc Biol. 2007;27:e33–4.View ArticleGoogle Scholar
  16. Hanford LE, Enghild JJ, Valnickova Z, Petersen SV, Schaefer LM, Schaefer TM, et al. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem. 2004;279:50019–24.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJJ, Chow WS, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998;4:1025–31.View ArticlePubMedGoogle Scholar
  18. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Nakatani Y, et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care. 2005;28:2716–21.View ArticlePubMedGoogle Scholar
  19. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, et al. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diab Vasc Dis Res. 2008;5:190–7.View ArticlePubMedGoogle Scholar
  20. Giannini C, D’Adamo E, de Giorgis T, Chiavaroli V, Verrotti A, Chiarelli F, et al. The possible role of esRAGE and sRAGE in the natural history of diabetic nephropathy in childhood. Pediatr Nephrol. 2011;27:269–75.View ArticlePubMedGoogle Scholar
  21. Lam JK, Wang Y, Shiu SW, Wong Y, Betteridge DJ, Tan KC. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE). Diabet Med. 2013;30:702–9.View ArticlePubMedGoogle Scholar
  22. Nin JW, Ferreira I, Schalkwijk CG, Prins MH, Chaturvedi N, Fuller JH, et al. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia. 2009;52:705–14.View ArticlePubMedGoogle Scholar
  23. Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux JL. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes (letter). Clin Chem. 2005;51(9):1749–50.View ArticlePubMedGoogle Scholar
  24. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis. 2009;204:288–92.View ArticlePubMedGoogle Scholar
  25. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH, et al. Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes. 2010;59:2027–32.PubMed CentralView ArticlePubMedGoogle Scholar
  26. Hudson BI, Moon YP, Kalea AZ, Khatri M, Marquez C, Schmidt AM, et al. Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). Atherosclerosis. 2011;216:192–8.PubMed CentralView ArticlePubMedGoogle Scholar
  27. Prasad K. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality. Int J Angiol. 2014;23:11–6.PubMed CentralView ArticlePubMedGoogle Scholar
  28. Margeirsdottir HD, Stensaeth KH, Larsen JR, Brunborg C, Dahl-Jorgensen K. Early signs of atherosclerosis in diabetic children on intensive insulin treatment: a population-based study. Diabetes Care. 2010;33:2043–8.PubMed CentralView ArticlePubMedGoogle Scholar
  29. Kilhovd BK, Giardino I, Torjesen PA, Birkeland KI, Berg TJ, Thornalley PJ, et al. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism. 2003;52:163–7.View ArticlePubMedGoogle Scholar
  30. Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Hanssen KF, et al. Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women. Atherosclerosis. 2009;205:590–4.View ArticlePubMedGoogle Scholar
  31. Berg TJ, Clausen JT, Torjesen PA, Dahl-Jorgensen K, Bangstad HJ, Hanssen KF. The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care. 1998;21:1997–2002.View ArticlePubMedGoogle Scholar
  32. Heier M, Margeirsdottir HD, Brunborg C, Hanssen KF, Dahl-Jorgensen K, Seljeflot I. Inflammation in childhood type 1 diabetes; influence of glycemic control. Atherosclerosis. 2014;238:33–7.View ArticlePubMedGoogle Scholar
  33. Fujii EY, Nakayama M. The measurements of RAGE, VEGF, and AGEs in the plasma and follicular fluid of reproductive women: the influence of aging. Fertil Steril. 2010;94:694–700.View ArticlePubMedGoogle Scholar
  34. Komosinska-Vassev K, Olczyk P, Winsz-Szczotka K, Klimek K, Olczyk K. Plasma biomarkers of oxidative and AGE-mediated damage of proteins and glycosaminoglycans during healthy ageing: a possible association with ECM metabolism. Mech Ageing Dev. 2012;133:538–48.View ArticlePubMedGoogle Scholar
  35. Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochemical Pharmacology BiochemPharmacol. 2010;79:1379–86.View ArticleGoogle Scholar
  36. Geroldi D, Falcone C, Minoretti P, Emanuele E, Arra M, D’Angelo A. High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans (letter). J Am Geriatr Soc. 2006;54(7):1149–50.View ArticlePubMedGoogle Scholar
  37. Yamagishi S, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed). 2010;2:1184–95.View ArticlePubMedGoogle Scholar
  38. Humpert PM, Djuric Z, Kopf S, Rudofsky G, Morcos M, Nawroth PP, et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol. 2007;6:9.PubMed CentralView ArticlePubMedGoogle Scholar
  39. Zhang L, Bukulin M, Kojro E, Roth A, Metz VV, Fahrenholz F, et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem. 2008;283:35507–16.View ArticlePubMedGoogle Scholar
  40. Galichet A, Weibel M, Heizmann CW. Calcium-regulated intramembrane proteolysis of the RAGE receptor. Biochem Biophys Res Commun. 2008;370:1–5.View ArticlePubMedGoogle Scholar
  41. Metz VV, Kojro E, Rat D, Postina R. Induction of RAGE shedding by activation of G protein-coupled receptors. PLoS One. 2012;7:e41823.PubMed CentralView ArticlePubMedGoogle Scholar
  42. Grossin N, Wautier MP, Picot J, Stern DM, Wautier JL. Differential effect of plasma or erythrocyte AGE-ligands of RAGE on expression of transcripts for receptor isoforms. Diabetes Metab. 2009;35:410–7.View ArticlePubMedGoogle Scholar
  43. Ohe K, Watanabe T, Harada S, Munesue S, Yamamoto Y, Yonekura H, et al. Regulation of alternative splicing of the receptor for advanced glycation endproducts (RAGE) through G-rich cis-elements and heterogenous nuclear ribonucleoprotein H. J Biochem. 2010;147:651–9.View ArticlePubMedGoogle Scholar
  44. Yu Y, Hanssen KF, Kalyanaraman V, Chirindel A, Jenkins AJ, Nankervis AJ, et al. Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in type 1 diabetes. BJOG. 2012;119:1512–20.PubMed CentralView ArticlePubMedGoogle Scholar
  45. Tardif JC, Heinonen T, Orloff D, Libby P. Vascular biomarkers and surrogates in cardiovascular disease. Circulation. 2006;113:2936–42.View ArticlePubMedGoogle Scholar
  46. Manigrasso MB, Juranek J, Ramasamy R, Schmidt AM. Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol Metab. 2014;25:15–22.View ArticlePubMedGoogle Scholar
  47. Kierdorf K, Fritz G. RAGE regulation and signaling in inflammation and beyond. J Leukoc Biol. 2013;94:55–68.View ArticlePubMedGoogle Scholar

Copyright

© Heier et al. 2015

Advertisement